BDSX vs. XGN, DCGO, KDLY, EUDA, CORBF, ATPC, QIPT, BMGL, SERA, and PIII
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), DocGo (DCGO), Kindly MD (KDLY), EUDA Health (EUDA), Global Cord Blood (CORBF), Agape ATP (ATPC), Quipt Home Medical (QIPT), Basel Medical Group (BMGL), Sera Prognostics (SERA), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.
Biodesix vs. Its Competitors
Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 30.1% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Biodesix received 7 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 76.09% of users gave Biodesix an outperform vote while only 62.22% of users gave Exagen an outperform vote.
Exagen has a net margin of -30.36% compared to Biodesix's net margin of -66.84%. Exagen's return on equity of -92.58% beat Biodesix's return on equity.
Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biodesix had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat Biodesix's score of 0.30 indicating that Exagen is being referred to more favorably in the media.
Exagen has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Exagen currently has a consensus target price of $7.50, indicating a potential upside of 3.31%. Biodesix has a consensus target price of $1.75, indicating a potential upside of 447.56%. Given Biodesix's higher probable upside, analysts plainly believe Biodesix is more favorable than Exagen.
Summary
Exagen beats Biodesix on 10 of the 18 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy BDSX Stock Free BDSX Stock Alerts